Mol Neurobiol 39:101106 Triebelhorn J, Cardon I, Kuffner K, Bader S, Jahner T, Meindl K, Rothhammer-Hampl T, Riemenschneider MJ, Drexler K, Berneburg M, Nothdurfter C, Manook A, Brochhausen C, Baghai TC, Hilbert S, Rupprecht R, Milenkovic VM, Wetzel CH (2022) Induced neural progenitor cells and ips-neurons from major depressive disorder patients show altered bioenergetics and electrophysiological properties
& Xiao, J
Rates of moderate or worse side effects ranged from 14% to 32%, but few people stopped treatment due to adverse events
In addition to the US FDA approved GLP-1RAs, there are GLP1/glucagon dual agonists (Cotadutide, BI 456906), GIP/GLP1 dual agonists (Tirzepatide, GIP/GLP peptide I and II), GIP/GLP1/glucagon tri-agonists (HM15211, GGG tri-agonist) and GLP1R agonists (Efpeglenatide, Rybelsus) currently in phase 1- III clinical trials for T2D, obesity, and NASH (MASH) treatments (12)
Constipation/Bloating While nausea is common, some people experience the opposite issue: constipation and bloating